Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...

(Michelle Mullins/for the Daily Southtown) Addy was diagnosed with metastatic hepatocellular carcinoma in July 2021. That ...

Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...

TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).

Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Hepatocellular Carcinoma.